Nabriva Therapeutics AG

Nabriva Therapeutics — Investor Presentation (April 2017)

35 slides from Nabriva Therapeutics's investor presentation, Apr 5, 2017

  1. Slide 1: Forward-looking statements

    This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our future expectations, plans and prospects, including but not limited to sta

  2. Slide 2: 2017 - A Transformational Year for Nabriva

    Expert team advancing pleuromutilins, a new class of antibiotics, for systemic (IV and oral) use in humans Lefamulin in two international, pivotal Phase 3 trials for moderate-to-severe CABP with top-line data expected in 3Q17 and in 1Q18 Investing in pre-commercial activities to maximize commercial

  3. Slide 3: Burden of Pneumonia is Increasing due to Significant Morbidity and Mortality

    In 2010, direct hospitalization costs of CAP were estimated at over $17 billiona H Pneumonia is responsible for ~140,000 hospital readmissions per year, estimated to cost more than $10B in hospital expendituresb In 2013, in the US, ~50K people died due to CABPd Commercial payor average cost of ~$28K

  4. Slide 4: Significant US Adult CABP Opportunity in Hospital-Initiated Therapy

    Significant US Adult CABP Opportunity in Hospital-Initiated Therapy ~4.2MM Oral Antibiotic Prescriptions for Hospital-Initiated Adult Outpatient CABP TreatmentB A Decision Resources Group/AMR, Age 18+ for 12 months ended December 2015 B Source Health Solutions (12 months ending September 2016), Age

  5. Slide 5: Bacterial Resistance Complicates the Choice of Appropriate Empiric Therapy

    Bacterial Resistance Complicates the Choice of Appropriate Empiric Therapy Sources: aMorrissey, I. ECCMID 2014. Abstract P1584 bKim, SH AAC, 2012, 56: 1418-1426 US Susceptibility Rates Have Decreased across Many Antibiotics for S. pneumoniae, the Most Common Cause of CABP Macrolide resistance is inc

  6. Slide 6: Antibiotic Stewardship Should Increasingly Drive Antibiotic Choices

    Achieve the best clinical outcome, while lessening or mitigating adverse events and limiting selective pressures Effective January 1, 2017, Joint Commission & CMS require that all hospitals have Antibiotic Stewardship Committees (ASC) Decrease excessive costs due to suboptimal antibiotic use Realize

  7. Slide 7: Lefamulin Addresses the Factors that Increasingly Influence Treatment Choices for CABP

    5-7 days IV/PO Monotherapy for Most* Patients Novel Mechanism of Action CABP Targeted Spectrum of Activity Stewardship Guidelines recommend use of targeted antibiotics, not broad spectrum, and shortest effective treatment duration Resistance to many current antibiotics is rising and increases the ne

  8. Slide 8: Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use

    Lefamulin A site P site PTC of the 23S rRNA of the large ribosomal subunit Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use Lefamulin: Novel mechanism of action with 4 distinctive binding sites in highly conserved core of the ribosomal peptidyl transferase center (PTC) Targ

  9. Slide 9: Lefamulin: First in Class Systemic Pleuromutilin for Targeted Empiric CABP Monotherapy

    Lefamulin: First in Class Systemic Pleuromutilin In Development for Targeted Empiric CABP Monotherapy Targeted spectrum of activity covering key CABP pathogens Gram-positive, Gram-negative, atypicals, including multi-drug resistant (MDR) strains Substantial penetration into lung fluids and macrophag

  10. Slide 10: Lefamulin Spectrum of in vitro Activity Well Suited for CABP

    Lefamulin Spectrum of in vitro Activity Well Suited for CABP Extensively investigated against most prevalent pathogens Not affected by increasing antibiotic resistance observed in CABP pathogens: Cephalosporin/ fluoroquinolone/ macrolide/ penicillin resistance in S. pneumoniae Macrolide-resistant My

  11. Slide 11: Lefamulin Data Supported Progression to Phase 3 CABP Clinical Trials

    Lefamulin Data Supported Progression to Phase 3 CABP Clinical Trials CABP Animal Studies PK/PD and Microbiology Phase 2 ABSSSI Proof of Concept Phase 1/2 IV and oral data in over 400 patients and healthy subjects

  12. Slide 12: Therapeutic Effect Observed in Phase 2 Trial of ABSSSI

    Therapeutic Effect Observed in Phase 2 Trial of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Lefamulin achieved clinical response rates comparable to vancomycin Lefamulin was well tolerated Most commonly reported adverse events included headache, nausea and infusion site pain or redne

  13. Slide 13: Lefamulin Related Tolerability Profile Observed in Phase 2 Trial of ABSSSI

    Lefamulin Related Tolerability Profile Observed in Phase 2 Trial of ABSSSI TABLE 10 Drug-related treatment-emergent AEs by preferred term reported by >2% of patients in ITT population No, (%) of patients BC-3781 100 mg 150 mg Vancomycin AE (n = 70) in = 71) 1 g(n = 66) Headache 5(7.1) 9(12.7) 10(15.

  14. Slide 14: Lefamulin Clinical Development Plan Supports Differentiation in CABP

    Lefamulin Clinical Development Plan Supports Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation of Adults with Pneumonia (LEAP 1) trial (IV to oral) in moderate-to-severe CABP (Pneumonia Outcomes Research Team (PORT) III, IV and V) Site selec

  15. Slide 15: LEAP Phase 3 Trial Designs Cover Multiple Treatment Settings for CABP

    LEAP Phase 3 Trial Designs Cover Multiple Treatment Settings for CABP LEAP 1 (IV to Oral) Trial ~550 adult patients with PORT Risk Class >III (moderate to severe) 1:1 randomization: lefamulin vs. moxifloxacin ± linezolid Rx for 7 days (10 days for MRSA) PORT Risk Class III vs. IV and V >25% of patie

  16. Slide 16: Lefamulin Has a Differentiated Profile in CABP Compared with Approved Classes

    Lefamulin Fluoro-quinolones Macrolides Cephalo-sporins PCN/ BLI Tetra-cyclines Oxazo-lidinones First-in class Targeted Spectrum Activity vs. MRSA Activity vs. atypicals Activity vs. H. influenzae IV to oral switch Low Propensity for Resistance Development Empiric monotherapy Note: Nabriva management

  17. Slide 17: Financial Highlights

    Financial Highlights $83.9MM Cash, cash equivalents and investments as of December 31, 2016 Pursuing plan for the redomiciliation from Austria to Ireland 2,719,695 Common shares as of Dec 19, 2016 (equivalent to ~27.2MM ADSs) Year end balance expected to fund operations at least into 2Q18

  18. Slide 18: Anticipated Lefamulin Milestones

    Anticipated Lefamulin Milestones February 2017 Blinded, interim analysis to confirm LEAP 1 sample size 1Q 2018 Top-line data from LEAP 2 Phase 3 trial for CABP 2H18 Regulatory filings in US and EU (priority review request to FDA) for CABP 3Q 2017 Top-line data from LEAP 1 Phase 3 trial for CABP

  19. Slide 19: Advancing Pleuromutilin Development Pipeline

    Advancing Pleuromutilin Development Pipeline Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* LEAP 1 and LEAP 2 top-line data expected in 3Q17 and in 1Q18 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indications Preclinical work and formu

  20. Slide 20: Key Takeaways for Transformational Year

    Lefamulin in two international, pivotal Phase 3 trials for moderate-to-severe CABP with top-line data expected in 3Q17 and in 1Q18 Investing in pre-commercial activities to maximize commercial potential Cash expected to fund operations at least into 2Q18 Key Takeaways for Transformational Year Exper

  21. Slide 21: Developing Novel Anti-Infectives (April 2017)

    April 2017 Developing Novel Anti-Infectives

  22. Slide 22: Lefamulin May Be Used in Multiple CABP Treatment Settings

    Non-ICU Inpatient B-lactam (IV or IM) + Macrolide (IV or PO) Respiratory Quinolone (IV or PO) B-lactam (IV or IM) + Doxycycline (IV or PO) ICU Inpatient B-lactam (IV) + Macrolide (IV) B-lactam (IV) + respiratory Quinolone (IV) B-lactam (IV) + Aminoglycoside (IV) + respiratory Quinolone (IV) Mandell

  23. Slide 23: MRSA Pneumonia Increases Patient Risk

    MRSA Pneumonia Increases Patient Risk Low confirmed prevalence Difficult to distinguish clinically from other pathogens Outcomes worse than with other causative pathogens: MRSA pneumonia associated with more severe clinical outcomes than those with pneumococcal CAP1 intensive care unit admission (86

  24. Slide 24: Market Research Indicates Lefamulin Patient Opportunity Across Generic CABP Regimens

    Market Research Indicates Lefamulin Patient Opportunity from Across Generic CABP Regimens IV In-Patient Market Share 2015 Source: AMR data CEPHALOSPORIN 30% FLUOROQUINOLONE 23% MACROLIDE 17% PENICILLIN - COMBO 10% GLYCOPEPTIDE 10% AMINOGLYCOSIDE 2% TETRACYCLINE 2% CARBAPENEM 2% LINCOSAMIDE 1% MONOBA

  25. Slide 25: Resistance and Safety Issues Could Slow Future Macrolide and Fluoroquinolone Use

    Resistance and Safety Issues Could Slow Future Macrolide and Fluoroquinolone Use Source: AMR data Oral In-Patient Market Share 2015 MACROLIDE 44% FLUOROQUINOLONE 34% CEPHALOSPORIN 9% PENICILLIN - COMBO 4% TETRACYCLINE 4% ANTIFOLATE 1% OXAZOLIDINONE 1% PENICILLIN 1% LINCOSAMIDE 1% NITROIMIDAZOLE 1% R

  26. Slide 26: Resistance is Growing Among Common Adult CABP Outpatient Oral Prescriptions

    Resistance is Growing Among Common Adult CABP Outpatient Oral Prescriptions Based on data provided by Source Health Solutions (12 months ending September 2016), Age 18+ CEFPODOXIME, 1% MINOCYCLINE, 1% MOXIFLOXACIN, 1% CLARITHROMYCIN, 1% PENICILLIN V, 1% Other, 2% CEFDINIR, 3% METRONIDAZOLE, 3% CEFUR

  27. Slide 27: LEAP 1 and 2: Powering and Primary Objectives

    LEAP 1 and 2: Powering and Primary Objectives FDA Endpoint: Early Clinical Response (ECR) 72-120 hours after first dose of study drug Intent to Treat (ITT) Population LEAP 1 non-inferiority margin 12.5%, >90% power LEAP 2 non-inferiority margin 10%, 90% power EMA endpoint: Investigator Assessment of

  28. Slide 28: LEAP 1 and 2: Treatment Scenarios

    LEAP 1 and 2: Treatment Scenarios LEAP 1 All patients: IV therapy for a minimum of three days before switching to oral therapy Patients will receive 7 days of lefamulin vs. 7 days moxifloxacin Patients receive 10 days if: MRSA pneumonia confirmed Both moxifloxacin and linezolid started at baseline (

  29. Slide 29: Lefamulin Pre-clinical Data Supports Advancing to Phase 3 for CABP

    Lefamulin Pre-clinical Data Supports Advancing to Phase 3 for CABP 24h AUC/MIC was identified as the PK/PD index most relevant for efficacy Time-dependent killing and modest in vitro and in vivo post antibiotic effects Substantial lung penetration, as demonstrated by epithelial lining fluid and macr

  30. Slide 30: Lefamulin Clinical Database Supported Advancing to Phase 3 for CABP

    Lefamulin Clinical Database Supported Advancing to Phase 3 for CABP Studied by IV and oral route in more than 400 patients and healthy subjects Generally well tolerated by IV and oral routes Transient, Cmax related QTc effect comparable to, or less than, that of moxifloxacin Rapid oral absorption (6

  31. Slide 31: Lefamulin Manufacturing On Track for NDA Submission in 2018

    Lefamulin Manufacturing On Track for NDA Submission in 2018 Nabriva CMC/Manufacturing Team- extensive experience with new product approvals in the US and Europe Nabriva Quality Assurance Team- extensive experience with regulatory agency requirements in the US and Europe Drug Substance (API) Well kno

  32. Slide 32: Nabriva Has a Strong and Broad Patent Portfolio

    Nabriva Has a Strong and Broad Patent Portfolio Nabriva currently has 19 worldwide pleuromutilin patent families active on file Most of the global pleuromutilin IP landscape is covered (including U.S., Europe, Japan) Lefamulin IP protected at least until 2028 by several layers Composition of matter

  33. Slide 33: Scientific, Regulatory and Government Agencies Focused on Infectious Diseases

    US legislation continues to drive discovery of novel antibiotics GAIN Act (Generating Antibiotic Incentives Now) ADAPT Act (Antibiotic Development to Advance Patient Treatment) DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms)- part of 21st Century Cures Act C

  34. Slide 34: WHO Top Priority Pathogens for which New Antibiotics are Urgently Needed

    WHO Top Priority Pathogens for which New Antibiotics are Urgently Needed PRIORITY Critical Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae carbapenem-resistant ESBL-producing PRIORITY High Staphylococcus aureus, methicillin-resistant, van

  35. Slide 35: WHO Top Priority Pathogens

    WHO Top Priority Pathogens for which New en are Urgently Needed @) World Health 3 Organization * Streptococcus pneumoniae, penicillin-non-susceptible PRIORITY * Haemophilus influenzae, ampicillin-resistant Lefamulin has in * Shigella spp., fluoroquinolone-resistant vitro Activity Against Four Resist

Nabriva Therapeutics — Investor Presentation (April 2017) on 6ix